Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
Novartis has grown weary of waiting, dropping out of its deal to fund Mesoblast’s floundering COVID-19 treatment.
A study out of the University of Oxford found that two shots of the Pfizer-BioNTech vaccine or the AstraZeneca-Oxford vaccine were not as effective at against Omicron as they were against previous variants.
Now, researchers are on the threshold of great changes that have the potential to transform non-curable diseases into those that can be cured.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
LAG-3 is a priority focus in cancer immunotherapy because its inhibition has the potential to make PD-1 inhibitors work in more patients.
Life sciences investors are being anything but shy as the end of 2021 draws near. Here are a few companies that are still seeing cash come in the door as December gets underway.
PRESS RELEASES